GlassScriptPhysician profile
Manika Girdhar
NPI 1003186479
$9,092.21
in general payments reported to CMS, 2019-2025
25 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $297 · 2021: $1,527 · 2022: $1,286 · 2023: $1,391 · 2024: $2,505 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,732.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,223.67 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,781.23 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,483.73 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $607.37 | 2019-2025 | |
| Pfizer INC. | $510.59 | 2020-2025 | |
| Optinose US, INC. | $383.78 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $368.65 | 2019-2023 | Armonair Digihaler |
| Incyte Corporation | $285.28 | 2022-2025 | Opzelura |
| Genzyme Corporation | $271.14 | 2021-2025 | |
| Kaleo, INC. | $207.12 | 2020-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $198.98 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $190.91 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Covis Pharma Gmbh | $117.74 | 2021 | |
| Biocryst US Sales Co., LLC | $94.09 | 2021-2025 | Orladeyo |
| Amgen INC. | $87.24 | 2022-2025 | Tezspire, Actimmune |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $56.87 | 2020-2022 | |
| Genentech USA, INC. | $36.90 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $33.55 | 2022-2024 | Ryaltris |
| Horizon Therapeutics Plc | $29.35 | 2021 | |
| Paratek Pharmaceuticals, INC. | $28.38 | 2025 | Xhance |
| Blueprint Medicines Corporation | $25.91 | 2024 | Ayvakit |
| Alk-Abello, INC | $24.95 | 2021 | |
| Greer Laboratories, INC. | $18.52 | 2024 | Palforzia |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manika Girdhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.